



NurExone

biologic

Where Nature Ends, NurExone Begins

Transforming Regenerative Medicine

Q4 2024 | Canada (TSXV: NRX) Germany (FRA: J90.F) US (OTCQB: NRXBF)



DISCLAIMER:

Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction.

This presentation contains “forward-looking information” for purposes of applicable securities laws (“forward-looking statements”). Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations or assumptions regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements can be identified by words such as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “seek”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, “contemplate” and other similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our financial performance, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. This forward-looking information includes, among other things, statements relating to: expectations regarding industry trends, overall market growth rates and our growth rates and growth strategies; our business plans and strategies; expectations regarding growth; our competitive position in our industry.

Although we base the forward-looking statements contained in this presentation


on assumptions that we believe are reasonable, we caution you that actual results and developments (including our financial performance, financial condition and liquidity, and the development of the industry in which we operate) may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future.

United States Securities Laws:

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of NurExone Biologic Inc in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of NurExone Biologic Inc have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons," as such term is defined in Regulation S under the U.S. Securities Act, unless an exemption from such registration is available.

NurExone does not declare and/or insure and/or imply on any specific result of any treatment which may be developed in the future based on the research and development process done or planned to be done by the Company.

A Transformative Approach to Regenerative Medicine



Lead asset is the first known **minimally invasive** therapy that promotes **nerve regeneration and functional recovery** after a traumatic spinal cord injury

Proprietary ExoTherapy platform provides **optionality to address a broad spectrum of indications**, expanding the market potential considerably

De-risked business model with **two assets in early development PLUS platform partnership model**, which provides the potential for multiple revenue streams



Global patent protection across five patent families which includes proprietary siRNA for lead asset which has proven to be effective in animal models

Harnessing the Healing Power of Exosomes

Nature's "Guided Missiles" Target Inflamed Tissue



- We use exosomes as **"guided missiles"**, targeting specific tissues
- Exosomes are small particles created when stem cells proliferate and they can possess **"homing"** capability, **targeting specific tissues and inflammation** in the body
- Our exosomes can be loaded with a **wide range of molecules, such as siRNA** to enhance their inherent therapeutic potential




Exosomes as drug delivery systems
Cargo – small molecules, nucleotides, proteins

Exosomes can be administered via various delivery routes

NurExone's Platform Technology - ExoTherapy

Regenerative properties and therapeutic impact.

Exosomes




Exosomes are biologically-guided nanocarriers that can deliver "molecular cargo" to a target anatomy




Active Pharmaceutical Ingredient (API)



The company synthesizes compounds with therapeutic properties and active pharmaceutical ingredients that yield a synergistic effect with the exosomes



ExoTherapy Nanodrug



Exosomes, after production, are loaded with a therapeutic compound (such as siRNA, short peptides, small molecules). Known APIs can be repurposed and loaded onto the exosomes under a proprietary loading process

ExoTherapy Platform Provides Several Benefits

Leveraging Exosomes as The Ultimate Drug Delivery System



Crosses The Blood-brain-barrier

For neuron regeneration, rewiring and recovery



Minimally Invasive Drug Administration

Due to the natural affinity of exosomes to inflamed or damaged tissues



Cell-free






No patient personalization and minimal immunogenicity



Off The Shelf

Ease of production, distribution, and point of administration

Pipeline Focused on Innovation & Collaboration

Program	Indication	Discovery	Preclinical Development	Regulatory Strategy	Studies for IND (toxicity, efficacy)	Phase I
ExoPTEN	Acute Spinal Cord Injury					
	Glaucoma					
PNN Targeting Sequences	Several - CNS Traumatic Injury					
Exosomes and Stem Cells	Chronic Spinal Cord Injury	  <p><i>Collaboration with Inteligex leverages their novel targeted human stem cell platform which replaces key cell types lost due to traumatic injury or neurodegeneration</i></p>				

Intellectual Property Portfolio

5 PCTs, 1 granted patent in the US

PATENT FAMILY	
Drug Administration	<ul style="list-style-type: none">➤ <i>Intranasal ExoPTEN (Granted in the US and pending in other countries*)</i>
Exosomes and Large Scale Production	<ul style="list-style-type: none">➤ <i>2 PCTs on Production and Composition of Matter of our exosomes</i>➤ <i>2D and 3D production to achieve exosome potency</i>
Active Pharmaceutical Ingredient (API)	<ul style="list-style-type: none">➤ <i>Provisional patents describing siRNA sequences to inhibit PTEN production (ExoPTEN)</i>
Exosome Loading Technology	<ul style="list-style-type: none">➤ <i>Incubation allows efficient loading</i>➤ <i>No genetic engineering</i>➤ <i>Loading doesn't interact with cell membrane biochemistry, uses natural pathway that maintains integrity of exosomes</i>➤ <i>Non-toxic, natural conjugate media</i>➤ <i>Loading occurs post-production</i>

Lead Clinical Indication

Acute Spinal Cord Injury (SCI)



Approximately **50,000 new cases** of SCI are reported annually in the Western world, with an estimated **~500,000 individuals living with SCI globally**



Addressable market for SCI treatments is estimated at \$7.5B per year, with potential for growth as new therapies improve QoL* and reduce long-term care costs



The **lifetime cost of care** for an SCI patient can range from **\$1.5 million to \$4.7 million** depending on the severity of the injury.



The current standard of care is limited, with **a significant need for therapies that offer functional recovery** and improved patient outcomes



* QoL = Quality of life

Spinal Cord Injury Therapy - ExoPTEN Nanodrug

Proven functional recovery in preclinical animal studies

This is the first known minimally invasive therapy that has successfully promoted nerve regeneration and functional recovery following complete spinal cord transection.

Recovery of motor function, sensation, and bladder control was observed in 75% of animals after a brief intranasal ExoPTEN treatment cycle




Spinal Cord Injury Therapy - ExoPTEN Advantages



Comparison	ExoPTEN Technology	Autologous Stem Cell	Allogeneic Stem Cell	Epidural Electrical Stimulation	Monoclonal antibody, growth factors
Potential to repair full transection	✓	✓	✓	✗	✗
Non immunogenic	✓	✓	✗	✓	✓
Off the shelf use	✓	✗	✓	✓	✓
Minimally nvasive	✓	✗	✗	✗	✗

Additional Indication

Glaucoma



Glaucoma affects an estimated 7-10 million individuals in the Western world, **and globally, around 76 million people are affected**



Current treatments are limited and focus on preventing additional damage rather than regenerating or repairing damaged nerves




The market for treatments is projected to grow significantly, with **estimates suggesting it could exceed US\$10B by 2030**




With an aging population, the number of glaucoma cases is expected to increase significantly, **with projections reaching over 110 million globally by 2040**

Glaucoma – ExoPTEN in Optic Nerve Recovery


Minimally Invasive treatment with ExoPTEN showed functional restoration of damaged eyes to healthy levels in animals



ONC in one eye (red) with no treatment, which resulted in a flat, near-zero retinal response.



ONC in one eye and was treated with ExoPTEN (green, ONC+PTEN), resulting in a retinal response similar to the healthy intact contralateral eye.




ONC in one eye and was treated with naïve exosomes (brown, ONC+EXO), resulting in a recordable but delayed and smaller retinal response.

Road Map

Clear Path towards Clinical Trials

Plans for fda and ema approvals and a near future human clinical trial



NurExone received Orphan Drug Designation (ODD) approval for its ExoPTEN for acute Spinal Cord Injury indication

The information presented in this slide is forward-looking information which the Company does not commit or undertake to guarantee in any way. Investors should undertake their own risk assessment and analysis. The milestones shown are only an estimate and the actual development steps and/or results may differ from the estimated schedule presented here. The information is intended for illustrative purposes, its achievement is conditional on many factors over which the Company has no influence. The results of the R&D activities may impact the Company's achievements and schedules.

ExoPTEN is Just the Tip of the Iceberg...

ExoTherapy Platform Potential Leveraging Licensing and Collaboration



Licensing agreements can provide additional sources of capital in areas such as ...

- ➔ **Approved or under-development drugs that cannot currently be delivered to the brain because they can't cross the blood-brain-barrier**
- ➔ **Repurpose of products in low dosing or safer manner (nanoparticles that can penetrate cells)**
- ➔ **Ability to load wide range of API, such as siRNA, miRNA, small peptides and small molecules.**
- ➔ **Potential combination with API/Biological drugs to achieve a synergistic effect**

Broad Capabilities for Market Penetration:

The ExoTherapy platform has the potential to capture multiple high-value indications within **oncology, neurodegenerative diseases, and many more disease areas allowing for substantial market share** in each. We will leverage our licensing and collaboration agreement model with major pharmaceutical companies to broaden the capabilities and reach these additional markets

Experienced Leadership Team



Dr. Lior Shaltiel

An entrepreneur and an award-winning scientist with extensive multidisciplinary international experience, specializing in chemical engineering, molecular biology, electrophysiology, pharmacology and drug delivery systems. Lior is the initiator and head of the BioMed-MBA program at the Hebrew University. Dr. Shaltiel holds B.Sc in Chemical engineering, BGUM.med.Sc in medical science (Physiology), and BGUPh.D - Pharmacology (LMU, Germany) Postdoctoral - Goethe University Frankfurt, Germany



Mr. Eran Ovadya

A professional track record from 1st tier global corporations and significant expertise in public life-science and publicly-traded companies. Eran served for over a decade in a variety of finance roles for biotech companies including Gamida Cell, West pharma Israel, Omrix Biopharmaceuticals, a division of Ethicon Biosurgery, a Johnson & Johnson company, Macrocare, and Leap Therapeutics. Eran holds an MBA, specializing in financing, and a BA in accounting & economics from the Open University, Israel.



Dr. Noa Avni

Led R&D, Bioanalytical and Preclinical activities at NanoGhost and Minovia Therapeutics- startups developing novel drug delivery systems based on Mesenchymal Stem Cells, and Mitochondrial therapies respectively. Noa has a strong background in protein biochemistry, and received her Ph.D. at the Technion Institute Of Technology under the supervision of Chemistry Noble Prize Laureate, Prof. Aaron Ciechanover.



Dr. Ina Sarel

A biotechnology executive with over 20 years of experience in product development from discovery and Proof of Concept through pre-clinical and clinical stages. Ina has broad expertise in stem/progenitor cell therapy, CMC, and regulatory requirements and previously developed a stem cell research product commercialized by Lonza. Ina holds a Ph.D. in Neuroendocrinology from Boston University, USA.

Seasoned Board of Directors



Israel



Dr. Gadi Riesenfeld

Director

Dr. Riesenfeld has served on the board of directors and as president of several bio pharmaceutical companies, including Kamapharm Ltd., Galisar Ltd., OticPharma and Pharmos Corporation, a publicly traded biotech company listed on NASDAQ



Dr. Lior Shaltiel

Chief Executive Officer

An entrepreneur and distinguished scientist with extensive international experience, specializing in chemical engineering, electrophysiology, pharmacology and drug delivery systems.



Yoram Drucker

Founder, VP Business Development & Active Chairman of the Board

Successful Israeli entrepreneur and expert in the establishment of successful Stem cell start-ups. Founder and co-founder of several biotech companies, such as Pluristem, BrainStorm, InnoCan Pharma



Canada



Oded Orgil, LL.B.

Mr. Orgil has over 25 years experience in Capital Markets as a Financial Advisor and Senior Executive for both bank owned and national Independent firms.. In his career on Bay Street Oded has participated in over \$10 Billion of capital market transitions and acquisitions.



James (Jay) Richardson

Mr. Richardson has served as CEO or Chairman of several listed public companies and in others CFO and private company situations. He has extensive public company governance experience from over a dozen Board memberships including serving as Interim Chairman of the Argus Corporation.

Expert Scientific Advisory Board



Prof. Teodoro Forcht Dagi, MD, MPH

Teodoro (Teo) Forcht Dagi is a neurosurgeon who serves as distinguished scholar and professor at Queen's University Belfast and the William J. Clinton Leadership Institute.



Prof. Gabriel Zeilig, MD

Prof. Gabi Zeilig is the director of the Department of Neurological Rehabilitation and the National Spinal Cord Injury Rehabilitation Unit at the Sheba Medical Center, Tel Hashomer, Israel since 1999.



Prof. Michael Belkin, MD

Prof. Belkin was the founder of the Eye Research Institute at the Sheba Medical Center who has been involved in the establishment of many medical start-ups.



Prof. Shulamit Levenberg, PhD

Prof. Levenberg is the Dean of the Biomedical Engineering Department, Technion. Prof. Levenberg conducts interdisciplinary research on stem cells and tissue engineering



Yona Geffen, PhD, MSc

Dr. Geffen advances CMC processes for preclinical and clinical activities at NurExone, focusing on developing analytical methods, qualifying potency assays, and optimizing dosing regimens.



Prof. Nahshon Knoller, MD

Prof. Knoller established and headed the General Trauma at Sheba Medical Center. Dr. Knoller is a Director of the Spine Surgery Unit who treats and analyzes the entire range of spine and head pathologies.

NurExone Biologic Investment Summary

Platform with multiple shots on goal and partnership model driving uncapped opportunities



ExoTherapy platform leverages the power of exosomes as a delivery & targeting mechanism providing optionality for a wide range of diseases



Two clinical programs targeting areas with a high unmet need and large (\$1B+) commercial opportunities with near term milestones



Hybrid business model derisks opportunity with both inhouse development and licensing model for ExoTherapy, providing multiple revenue streams



Experienced management and advisory team outlines a clear development roadmap, supported by a robust intellectual property portfolio

TSXV: NRX | TSXV: NRX | OTCQB: NRXBF



THANK YOU

For more information please contact:

Yoram Drucker, VP Strategic Operations

+ 972 54 4711171

yoram@nurexone.com

DISCLOSURE

The matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of the company could differ significantly from those statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This document does not constitute an offer to sell or a solicitation of offers to buy any securities of the company or any entity.